GnRH agonist leuprolide depot 6-month
Selected indexed studies
- Clinical development of the GnRH agonist leuprolide acetate depot. (F S Rep, 2023) [PMID:37223757]
- Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study. (J Endocr Soc, 2023) [PMID:37334213]
- Leveraging Model-Based Simulations to Optimize Extended Dosing of Leuprolide 6-Month Intramuscular Depot Formulation. (Eur J Drug Metab Pharmacokinet, 2025) [PMID:39881064]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Leveraging Model-Based Simulations to Optimize Extended Dosing of Leuprolide 6-Month Intramuscular Depot Formulation. (2025) pubmed
- Clinical development of the GnRH agonist leuprolide acetate depot. (2023) pubmed
- Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. (2012) pubmed
- 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. (2014) pubmed
- Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. (2009) pubmed
- Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study. (2023) pubmed
- Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. (2015) pubmed
- Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. (2011) pubmed
- A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients. (2020) pubmed
- Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer. (2014) pubmed